Merck and Eisai have announced promising results from the Phase 3 LITESPARK-011 trial, which evaluated a dual therapy regimen for patients with advanced renal cell carcinoma (RCC). The study focused on individuals whose cancer had progressed following treatment with immunotherapy, targeting a segment of patients often left with limited options after failure of standard regimens.
The combination involved Merck’s belzutifan (Welireg), a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, and Eisai’s lenvatinib (Lenvima), a multi-targeted receptor tyrosine kinase inhibitor. Results from the trial demonstrated a statistically significant and clinically meaningful extension of progression-free survival compared to cabozantinib, a commonly used therapy in this setting. The positive finding positions the combo as the first to show such benefit for RCC patients post-immunotherapy.
Additionally, the duo improved objective response rates, indicating more patients responded favorably to the treatment compared to the control group. However, the study’s other main endpoint—overall survival—showed only a trend towards improvement and did not reach statistical significance during this interim analysis. Ongoing monitoring will continue to assess long-term survival benefits.
Both therapies maintained safety profiles consistent with previous data, and no new risks were identified during the trial. Merck and Eisai will engage with global regulators and intend to share detailed results at upcoming medical conferences. The potential regulatory approval of this combination could mark a notable advance for individuals facing advanced kidney cancer after immunotherapy.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!